Evaluation of mortality, prognostic parameters, and treatment efficacy in mycosis fungoides
© 2024 The Authors. Journal der Deutschen Dermatologischen Gesellschaft published by Wiley‐VCH GmbH on behalf of Deutsche Dermatologische Gesellschaft..
BACKGROUND AND OBJECTIVES: Mycosis fungoides (MF), the most common primary cutaneous T-cell lymphoma, is characterized by a variable clinical course, presenting either as indolent disease or showing fatal progression due to extracutaneous involvement. Importantly, the lack of prognostic models and predominantly palliative therapy settings hamper patient care. Here, we aimed to define survival rates, disease prediction accuracy, and treatment impact in MF.
PATIENTS AND METHODS: Hundred-forty MF patients were assessed retrospectively. Prognosis and disease progression/survival were analyzed using univariate Cox proportional hazards regression model and Kaplan-Meier estimates.
RESULTS: Skin tumors were linked to shorter progression-free, overall survival and a 3.48 increased risk for disease progression when compared to erythroderma. The Cutaneous Lymphoma International Prognostic Index identified patients at risk in early-stage disease only. Moreover, expression of Ki-67 >20%, CD30 >10%, CD20+, and CD7- were associated with a significantly worse outcome independent of disease stage. Only single-agent interferon-α and phototherapy combined with interferon-α or retinoids/bexarotene achieved long-term disease control in MF.
CONCLUSIONS: Our data support predictive validity of prognostic factors and models in MF and identified further potential parameters associated with poor survival. Prospective studies on prognostic indices across disease stages and treatment modalities are needed to predict and improve survival.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG - 22(2024), 4 vom: 05. Apr., Seite 532-550 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Porkert, Stefanie [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cutaneous T‐cell lymphoma |
|---|
| Anmerkungen: |
Date Completed 08.04.2024 Date Revised 08.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/ddg.15331 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369340981 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369340981 | ||
| 003 | DE-627 | ||
| 005 | 20240408232546.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240306s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/ddg.15331 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1369.xml |
| 035 | |a (DE-627)NLM369340981 | ||
| 035 | |a (NLM)38444271 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Porkert, Stefanie |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evaluation of mortality, prognostic parameters, and treatment efficacy in mycosis fungoides |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.04.2024 | ||
| 500 | |a Date Revised 08.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024 The Authors. Journal der Deutschen Dermatologischen Gesellschaft published by Wiley‐VCH GmbH on behalf of Deutsche Dermatologische Gesellschaft. | ||
| 520 | |a BACKGROUND AND OBJECTIVES: Mycosis fungoides (MF), the most common primary cutaneous T-cell lymphoma, is characterized by a variable clinical course, presenting either as indolent disease or showing fatal progression due to extracutaneous involvement. Importantly, the lack of prognostic models and predominantly palliative therapy settings hamper patient care. Here, we aimed to define survival rates, disease prediction accuracy, and treatment impact in MF | ||
| 520 | |a PATIENTS AND METHODS: Hundred-forty MF patients were assessed retrospectively. Prognosis and disease progression/survival were analyzed using univariate Cox proportional hazards regression model and Kaplan-Meier estimates | ||
| 520 | |a RESULTS: Skin tumors were linked to shorter progression-free, overall survival and a 3.48 increased risk for disease progression when compared to erythroderma. The Cutaneous Lymphoma International Prognostic Index identified patients at risk in early-stage disease only. Moreover, expression of Ki-67 >20%, CD30 >10%, CD20+, and CD7- were associated with a significantly worse outcome independent of disease stage. Only single-agent interferon-α and phototherapy combined with interferon-α or retinoids/bexarotene achieved long-term disease control in MF | ||
| 520 | |a CONCLUSIONS: Our data support predictive validity of prognostic factors and models in MF and identified further potential parameters associated with poor survival. Prospective studies on prognostic indices across disease stages and treatment modalities are needed to predict and improve survival | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Mycosis fungoides | |
| 650 | 4 | |a TTNT | |
| 650 | 4 | |a cutaneous T‐cell lymphoma | |
| 650 | 4 | |a mortality | |
| 650 | 4 | |a prognostic models | |
| 650 | 7 | |a Interferon-alpha |2 NLM | |
| 700 | 1 | |a Griss, Johannes |e verfasserin |4 aut | |
| 700 | 1 | |a Hudelist-Venz, Mercedes |e verfasserin |4 aut | |
| 700 | 1 | |a Steiner, Irene |e verfasserin |4 aut | |
| 700 | 1 | |a Valencak, Julia |e verfasserin |4 aut | |
| 700 | 1 | |a Weninger, Wolfgang |e verfasserin |4 aut | |
| 700 | 1 | |a Brunner, Patrick M |e verfasserin |4 aut | |
| 700 | 1 | |a Jonak, Constanze |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG |d 2003 |g 22(2024), 4 vom: 05. Apr., Seite 532-550 |w (DE-627)NLM155366637 |x 1610-0387 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2024 |g number:4 |g day:05 |g month:04 |g pages:532-550 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/ddg.15331 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2024 |e 4 |b 05 |c 04 |h 532-550 | ||